The Future of Genomic Medicine conference last week down in La Jolla at Scripps was one of my favorite meetings ever. I wish I had time to have live blogged it more beyond the one post I did about some gene editing talks. Below I discuss 10 top takeaways from this great meeting that I’m planning to attend […]
10 takeaways from Future of Genomic Medicine meeting Read More »
For me it’s been a wild week of grant and paper writing, grant review, going over data, and more, but finally I had a chance to watch this week’s Dr. Oz show on stem cell clinics in full last night and I give it an A+ grade. A show producer went undercover with an MS patient to a
Kudos to Dr. Oz for stellar stem cell clinic show: time for more action Read More »
The Scientists March on Washington (aka March for Science @ScienceMarchDC) is one of the biggest science movements I’ve ever seen. It’s gone from zero to sixty in about 2 seconds now with hundreds of thousands of supporters, but some important questions are arising about this event and its organizers. I continue to be enthusiastic about the March, but this week I’ve
4 key questions for March for Science organizers & what info I gathered on them Read More »
What happens for patients and clinics after a stem cell facelift gone wrong? What about other cell injection problems? Cell therapies raise new challenges and risks. You can stop taking a pill or an injection treatment. However, you can’t stop or retract stem cell treatments if there’s a bad side effect. Unlike other kinds of
Clinics can’t retract problems like stem cell facelift gone wrong Read More »
Last week I posted my list of 2017 predictions for the stem cell field. Today a couple of days into 2017 I’m more focused on hope than realism. What would I wish for in the stem cell and regenerative medicine arena in the coming year? More stem cell clinical trial data posted and published. There are
Stem cell wish list for 2017 Read More »
Each year I make a list of predictions for the stem cell and regenerative medicine field for the coming new year. Later in this post I list my top 20 stem cell predictions for 2017. In looking at my past predictions I realized this will now be my 7th year doing stem cell/regenerative medicine yearly predictions.
Stem Cell Predictions for 2017 Read More »
Below are the 2016 stem cell predictions I made last year and their status now color-coded near year’s end. Green is right, orange is mixed bag, and red is flat out wrong. Overall, I did better than most past years with only having entirely blown it on four. Stay tuned later this week for my 2017 predictions,
Grading my stem cell predictions for 2016: how’d I do? Read More »
Recently I had the opportunity to talk with the leadership of Asterias, a California biotech doing exciting clinical research using stem cells as the basis for treatment of spinal cord injury. The interview covers the past (Geron patients), present, and future. I spoke with Asterias President and CEO Stephen Cartt and CMO Edward Wirth. How
Asterias interview: stem cell spinal cord injury trials advance Read More »
The 21st Century Cures Act has some important provisions that would impact the stem cell and regenerative medicine field. What is driving these efforts is a widespread sense that the status quo of regenerative medicine oversight isn’t working very well. I’m talking with key stakeholders and still trying to sort out my thoughts on the
Perspectives on Cures Act stem cell provisions possible benefits & risks Read More »
One of the hottest topics in the world of stem cells this year has been the REGROW ACT and at a larger level the movement for changes in FDA oversight of investigational regenerative medicine therapies (see my past posts on it here), so the related provisions in the 21st Century Cures Act are stirring much
Chat with Michael Werner of ARM on Cures Act regenerative medicine provisions Read More »